about to run, page-154

re: ready to fly. I know this news is a few weeks old, but for those that have not read, worth another read, this stock is going to fly soon.

Cancer treatment patent for Prima Biomed
May 10, 2005 - 4:20PM

Biotechnology company Prima Biomed has received a European patent for its CancerVac immunotherapeutic product, MFP, currently being tested in phase IIa clinical trials for ovarian cancer.

The company was granted a patent by the European Patent Office which is said to strengthen the technology and protect Prima Biomed from direct competition.

Prima Biomed said the administration of MFP to cancer patients had been shown to increase recognition by the immune system of a protein called mucin 1 which is known to be present on the cell surface of many different types of cancer.

The drug causes the production of a class of immune cell called cytotoxic T cells which act via mucin 1 to help stabilise or reduce tumours in cancer patients.

CancerVac, a subsidiary of Prima BioMed, secured worldwide exclusive rights to the use of mucin 1 in dendritic cell therapy from Canadian-based cancer immunotherapy company, Biomira Inc in March last year.

In turn, Biomira secured an option to license the CancerVac technology portfolio upon conclusion of the phase IIa clinical trials.

Advertisement
AdvertisementThe European patent is the fourth to cover the MFP product, with two already granted in the United States and one in Australia, which are valid until 2014.